论文部分内容阅读
目的:考察甲苯磺酸索拉非尼在十二指肠、空肠、回肠、结肠的吸收情况。方法:采用大鼠在体单向灌流法,研究甲苯磺酸索拉非尼在大鼠各肠段的吸收动力学性质及不同药物浓度、P-gp抑制剂维拉帕米对其吸收的影响。结果与结论:甲苯磺酸索拉非尼在肠道中的吸收按结肠、十二指肠、空肠、回肠的顺序依次下降;浓度为5mg.L-1时,其Ka和Peff显著高于其他两个浓度(P<0.05);P-gp抑制剂维拉帕米对甲苯磺酸索拉非尼的吸收无影响(P>0.05)。
Objective: To investigate the sorafenib tosylate absorption in the duodenum, jejunum, ileum, colon. Methods: In vivo rat single-pass perfusion method was used to study the absorption kinetics of sorafenib tosylate in different intestine and the effect of different concentrations of verapamil on the absorption of verapamil . RESULTS AND CONCLUSION: The absorption of sorafenib tosylate in the intestine decreased in the order of colon, duodenum, jejunum and ileum. At the concentration of 5 mg.L-1, Ka and Peff were significantly higher than those of the other two (P <0.05). P-gp inhibitor verapamil had no effect on the absorption of sorafenib tosylate (P> 0.05).